Phase IIa clinical trials ORY-2001 in multiple sclerosis (SATEEN study) and Alzheimer's disease (ETHERAL study)

With an extensive patent portfolio, Oryzon Genomics is the biotechnology leader in Spain and the leading epigenetics company in Europe.

Read more

Oryzon is the leader in the development of therapeutics in the epigenetic target LSD1: Oryzon has a program in oncology, ORY-1001, with a Phase I-IIA completed in Leukemia and a Phase I completed in small cell lung cancer (SCLC) and with two Phase IIA clinical studies in leukemia and SCLC in preparation, another program in the field of neurodegenerative and neuroinflammatory diseases, ORY-2001, with a Phase IIA already started in multiple sclerosis and a planned Phase IIA in Alzheimer's, and a third program, ORY-3001, currently finishing the preclinical regulatory phase, focused on the treatment of non-oncological diseases.

Oryzon also has other programs at early preclinical stage in other epigenetic therapeutic targets.

Source: Noble Capital Markets’ Fourteenth Annual Investor Conference.  January 30th, 2018

Oryzon is in permanent contact with the main pharmaceutical companies with the objective of establishing collaborative alliances based on its research and development programs. To that end, Oryzon also has an extensive network of contacts and collaboration agreements with public and private scientific reference institutions, either directly or under the framework of public grants at domestic as well as international level.

Read more